FrancophonIA/ELRC3.0 huggingface dataset:
English: Lorviqua 100 mg is supplied as oval dark pink film-coated tablets, debossed with “Pfizer” on one side and “LLN 100” on the other side.
Croatian: Lorviqua 100 mg dostupna je u obliku ovalnih tamnoružičastih filmom obloženih tableta s utisnutom oznakom „Pfizer“ na jednoj strani i „LLN 100“ na drugoj strani.
English: Resume lorlatinib at 1 reduced dose level.
Croatian: Nastavite primjenjivati dozu lorlatiniba smanjenu za 1 razinu.
English: depression, euphoric mood, irritability, mania, mood altered, mood swings, personality change, stress).
Croatian: Učinci na raspoloženje (uključuju afektivni poremećaj, afektivnu labilnost, agresivnost, agitaciju, anksioznost, depresivno raspoloženje, depresiju, euforično raspoloženje, razdražljivost, maniju, promijenjeno raspoloženje, promjene raspoloženja, promjenu osobnosti, stres).
English: If pacemaker placed, resume lorlatinib at full dose.
Croatian: Ako je elektrostimulator srca ugrađen, nastavite primjenjivati punu dozu lorlatiniba.
English: Withhold lorlatinib.
Croatian: Ne primjenjujte lorlatinib.
English: Mild hypertriglyceridaemia (triglycerides between 150 and 300 mg/dL or 1.71 and 3.42 mmol/L)
Croatian: blaga hipertrigliceridemija (trigliceridi između 150 i 300 mg/dl ili 1,71 i 3,42 mmol/l)
English: Lorviqua 100 mg: each film-coated tablet (tablet) contains 100 mg lorlatinib.
Croatian: Lorviqua 100 mg: jedna filmom obložena tableta (tableta) sadrži 100 mg lorlatiniba.
English: Eye disorders Vision disorderh
Croatian: Poremećaji oka Poremećaj vida
English: Severe or life-threatening pulmonary adverse reactions consistent with ILD/pneumonitis have occurred with lorlatinib (see section 4.8).
Croatian: Uz primjenu lorlatiniba pojavile su se teške plućne nuspojave ili plućne nuspojave opasne po život, koje se podudaraju s intersticijskom plućnom bolesti/pneumonitisom (vidjeti dio 4.8).
English: Dose modification may be required for those patients who develop AV block (see section 4.2).
Croatian: U bolesnika koji razviju AV blok može biti potrebna prilagodba doze (vidjeti dio 4.2).
English: No dose adjustments are recommended for patients with mild hepatic impairment.
Croatian: Ne preporučuju se prilagodbe doze u bolesnika s blagim oštećenjem jetre.
English: During treatment with lorlatinib and for at least 14 weeks after the final dose, male patients with female partners of childbearing potential must use effective contraception, including a condom, and male patients with pregnant partners must use condoms (see section 4.6).
Croatian: Muški bolesnici sa ženskim partnericama reproduktivne dobi moraju koristiti učinkovitu kontracepciju, uključujući prezervativ, dok muški bolesnici s trudnim partnericama moraju koristiti prezervative tijekom liječenja lorlatinibom i još najmanje 14 tjedana nakon posljednje doze (vidjeti dio 4.6).
English: Life-threatening hypertriglyceridaemia (triglycerides over 1,000 mg/dL or over 11.4 mmol/L)
Croatian: hipertrigliceridemija koja je opasna po život (trigliceridi iznad 1000 mg/dl ili iznad 11,4 mmol/l)
English: Lorviqua may affect male fertility.
Croatian: - Plodnost Lorviqua može utjecati na plodnost muškarca.
English: Severe hypertriglyceridaemia (triglycerides between 501 and 1,000 mg/dL or 5.71 and 11.4 mmol/L)
Croatian: teška hipertrigliceridemija (trigliceridi između 501 i 1000 mg/dl ili 5,71 i 11,4 mmol/l)
English: Very common Very common
Croatian: Vrlo često Vrlo često Vrlo često
English: s r.o.
Croatian: Prema ICR-u.
English: CYP3A4/5 inhibitors
Croatian: Inhibitori CYP3A4/5
English: Severe hypercholesterolaemia (cholesterol between 401 and 500 mg/dL or between 10.35 and 12.92 mmol/L)
Croatian: Doziranje lorlatiniba teška hiperkolesterolemija (kolesterol između 401 i 500 mg/dl ili između 10,35 i 12,92 mmol/l)
English: Hypercholesterolaemia/hypertriglyceridaemia
Croatian: Hiperkolesterolemija/hipertrigliceridemija
English: Concomitant use of a strong CYP3A4/5 inducer is contraindicated (see sections 4.3 and 4.5).
Croatian: Istodobna primjena snažnog induktora CYP3A4/5 je kontraindicirana (vidjeti dijelove 4.3 i 4.5).
English: Based on the available clinical study data, it is not possible to determine a causal relationship between effects on changes in cardiac contractility and lorlatinib.
Croatian: Nije moguće odrediti uzročni odnos između učinaka na promjene u srčanoj kontraktilnosti i lorlatiniba na temelju dostupnih podataka iz kliničkog ispitivanja.
English: Oval (8.5 × 17 mm) dark pink immediate release film-coated tablet, debossed with “Pfizer” on one side and “LLN 100” on the other side.
Croatian: Ovalna (8,5 × 17 mm) tamnoružičasta filmom obložena tableta s trenutnim otpuštanjem, s utisnutom oznakom „Pfizer“ na jednoj strani i „LLN 100“ na drugoj strani.
English: - Contraception - information for men You should not father children during treatment with Lorviqua because this medicine could harm the baby.
Croatian: - Kontracepcija - informacije za muškarce Tijekom liječenja lijekom Lorviqua
English: Moderate hypertriglyceridaemia (triglycerides between 301 and 500 mg/dL or 3.43 and 5.7 mmol/L)
Croatian: umjerena hipertrigliceridemija (trigliceridi između 301 i 500 mg/dl ili 3,43 i 5,7 mmol/l)
English: No dose adjustment is needed for patients with normal renal function and mild or moderate (CLcr: ≥ 30mL/min) renal impairment based on a population pharmacokinetic analysis.
Croatian: Na temelju populacijske farmakokinetičke analize prilagodba doze nije potrebna u bolesnika s normalnom funkcijom bubrega i blagim ili umjerenim (CLcr: ≥ 30 ml/min) oštećenjem funkcije bubrega.
English: (4.2, NR)
Croatian: 5,6 (4,2; ND)
English: Iron oxide black (E172)
Croatian: Film-ovojnica hipromeloza laktoza hidrat makrogol triacetin titanijev dioksid (E171) crni željezov oksid (E172) crveni željezov oksid (E172)
English: At single dose, lorlatinib systemic exposure (AUCinf and Cmax) increased in a dose-related manner over the 10 to 200 mg dose range.
Croatian: Pri primjeni pojedinačne doze u rasponu doza od 10 do 200 mg, sistemska izloženost (AUCinf i Cmax) lorlatinibu povećavala se ovisno o dozi.
English: Introduce the use of lipid-lowering therapy;b if currently on lipid-lowering therapy, increase the dose of this therapyb in accordance with respective prescribing information; or change to a new lipid-lowering therapyb.
Croatian: ako bolesnik već prima terapiju za smanjenje koncentracije lipida, povećajte dozu te terapije b u skladu s odgovarajućim uputama o propisivanju; ili prijeđite na novu terapiju za smanjenje koncentracije lipida b.
English: Round (8 mm) light pink immediate release film-coated tablet, debossed with “Pfizer” on one side and “25” and “LLN” on the other side.
Croatian: Okrugla (8 mm) svjetloružičasta filmom obložena tableta s trenutnim otpuštanjem, s utisnutom oznakom „Pfizer“ na jednoj strani te „25“ i „LLN“ na drugoj strani.
English: Each film-coated tablet contains 1.58 mg of lactose monohydrate.
Croatian: Pomoćna tvar s poznatim učinkom Jedna filmom obložena tableta sadrži 1,58 mg laktoze hidrata.
English: During treatment with lorlatinib and for at least 14 weeks after the final dose, male patients with female partners of childbearing potential must use effective contraception, including a condom, and male patients with pregnant partners must use condoms.
Croatian: Muški bolesnici sa ženskim partnericama reproduktivne dobi moraju koristiti učinkovitu kontracepciju, uključujući prezervativ, dok muški bolesnici s trudnim partnericama moraju koristiti prezervative tijekom liječenja lorlatinibom i još najmanje 14 tjedana nakon posljednje doze.
English: Thus, concurrent administration of lorlatinib with CYP3A4/5 substrates with narrow therapeutic indices, including but not limited to alfentanil, ciclosporin, dihydroergotamine, ergotamine, fentanyl, hormonal contraceptives, pimozide, quinidine, sirolimus and tacrolimus, should be avoided since the concentration of these medicinal products may be reduced by lorlatinib (see section 4.4).
Croatian: Stoga je potrebno izbjegavati istodobnu primjenu lorlatiniba sa supstratima CYP3A4/5 uskog terapijskog indeksa, uključujući između ostalog alfentanil, ciklosporin, dihidroergotamin, ergotamin, fentanil, hormonalna kontracepcijska sredstva, pimozid, kinidin, sirolimus i takrolimus, budući da lorlatinib može smanjiti koncentraciju tih lijekova (vidjeti dio 4.4).
English: CYP3A4/5 inducers
Croatian: Induktori CYP3A4/5
English: Dose modifications
Croatian: Prilagodbe doze
English: dementia, disturbance in attention, memory impairment, mental impairment; and also including events from SOC Psychiatric disorders: attention deficit/hyperactivity disorder, confusional state, delirium, disorientation, reading disorder).
Croatian: Učinci na kognitivne funkcije (uključuju događaje iz klasifikacije organskih sustava navedene u dijelu „Poremećaji živčanog sustava“: amneziju, kognitivni poremećaj, demenciju, poremećaj pažnje, poremećaj pamćenja, mentalno oštećenje i također uključuju događaje iz klasifikacije organskih sustava navedene u dijelu „Psihijatrijski poremećaji“: deficit pažnje/hiperaktivni poremećaj, stanje konfuzije, delirij, dezorijentiranost, poremećaj čitanja).
English: In vitro studies indicated that lorlatinib may have the potential to inhibit UGT1A1.
Croatian: In vitro ispitivanja inhibicije uridin-difosfat-glukuronoziltransferaze (UGT) In vitro ispitivanja pokazala su da lorlatinib može imati potencijal za inhibiciju UGT1A1.
English: Lorlatinib may have the potential to inhibit CYP2C9.
Croatian: In vitro ispitivanja drugih inhibicija i indukcija enzima CYP Lorlatinib može imati potencijal za inhibiciju CYP2C9.
English: Intracranial* efficacy results in Study A by prior treatment Efficacy parameter
Croatian: Rezultati intrakranijalne* djelotvornosti u ispitivanju
English: Concurrent administration of lorlatinib with CYP3A4/5 substrates with narrow therapeutic indices, including but not limited to alfentanil, ciclosporin, dihydroergotamine, ergotamine, fentanyl, hormonal contraceptives, pimozide, quinidine, sirolimus and tacrolimus, should be avoided since the concentration of these medicinal products may be reduced by lorlatinib (see section 4.5).
Croatian: Potrebno je izbjegavati istodobnu primjenu lorlatiniba sa supstratima CYP3A4/5 uskog terapijskog indeksa, uključujući između ostalog alfentanil, ciklosporin, dihidroergotamin, ergotamin, fentanil, hormonalna kontracepcijska sredstva, pimozid, kinidin, sirolimus i takrolimus, budući da lorlatinib može smanjiti koncentraciju tih lijekova (vidjeti dio 4.5).
English: Second degree AV block Asymptomatic
Croatian: AV blok drugog stupnja asimptomatski
English: How to take Lorviqua
Croatian: Kako uzimati lijek Lorviqua
English: How Lorviqua works
Croatian: Kako djeluje lijek Lorviqua
English: Elevations of lipase and/or amylase have occurred in patients receiving lorlatinib (see section 4.8).
Croatian: U bolesnika koji su primali lorlatinib pojavile su se povećane razine lipaze i/ili amilaze (vidjeti dio 4.8).
English: Dietary sodium
Croatian: Sadržaj natrija
English: - mood or memory problems, such as change in your mood (including depression, euphoria and mood swings), irritability, aggression, agitation, anxiety or a change in your personality and episodes of confusion.
Croatian: Liječnik će možda provesti dodatne preglede i smanjiti Vam dozu lijeka Lorviqua ili prekinuti liječenje. - problemi s raspoloženjem ili pamćenjem, kao što su: promjena raspoloženja (uključujući depresiju, euforiju i nagle promjene raspoloženja), razdražljivost, agresivnost, uznemirenost, tjeskoba ili promjena u Vašoj osobnosti i epizode smetenosti.
English: Pfizer Kft. Tel.: +36-1-488-37-00
Croatian: Tel.: +36-1-488-37-00
English: - Contraception - information for women You should not become pregnant while taking this medicine.
Croatian: Ne smijete zatrudnjeti dok uzimate ovaj lijek.
English: Each film-coated tablet contains 4.20 mg of lactose monohydrate.
Croatian: Pomoćna tvar s poznatim učinkom Jedna filmom obložena tableta sadrži 4,20 mg laktoze hidrata.
English: Your doctor may investigate further and may decide to reduce your dose of Lorviqua or stop your treatment.
Croatian: Liječnik će možda provesti dodatne preglede i smanjiti Vam dozu lijeka Lorviqua ili prekinuti liječenje.
English: Amylase increased Electrocardiogram PR prolongation
Croatian: Povećana tjelesna težina Povećane razine lipaze Povećane razine amilaze Produljenje PR intervala na EKG-u
English: What Lorviqua looks like and contents of the pack Lorviqua 25 mg is supplied as round light pink film-coated tablets, debossed with “Pfizer” on one side and “25” and “LLN” on the other side.
Croatian: Lorviqua 25 mg dostupna je u obliku okruglih svjetloružičastih filmom obloženih tableta s utisnutom oznakom „Pfizer“ na jednoj strani te „25“ i „LLN“ na drugoj strani.
English: Lorviqua 100 mg film-coated tablets
Croatian: Lorviqua 100 mg filmom obložene tablete
English: Pfizer Luxembourg SARL filialas Lietuvoje Tel. + 370 52 51 4000
Croatian: Pfizer Luxembourg SARL filiāle Latvijā Tel.: + 371 670 35 775
English: Lorviqua 25 mg film-coated tablets
Croatian: Lorviqua 25 mg filmom obložene tablete
English: Then resume lorlatinib at 1 reduced dose level.
Croatian: Potom nastavite primjenjivati dozu lorlatiniba smanjenu za 1 razinu.
English: Metabolism and nutrition disorders Hypercholesterolaemiaa Hypertriglyceridaemiab
Croatian: Poremećaji metabolizma i prehrane Hiperkolesterolemija
English: Overall efficacy results in Study A by prior treatment
Croatian: Ukupni rezultati djelotvornosti u ispitivanju
English: Lorviqua 25 mg film-coated tablets Lorviqua 100 mg film-coated tablets
Croatian: Lorviqua 25 mg filmom obložene tablete Lorviqua 100 mg filmom obložene tablete
English: MARKETING AUTHORISATION NUMBER(S) EU/1/19/1355/002
Croatian: EU/1/19/1355/002
English: Lorviqua 25 mg film-coated tablets Lorviqua 100 mg film-coated tablets lorlatinib
Croatian: Lorviqua 25 mg filmom obložene tablete Lorviqua 100 mg filmom obložene tablete lorlatinib
English: NAME OF THE MEDICINAL PRODUCT Lorviqua 100 mg tablets lorlatinib
Croatian: Lorviqua 100 mg tablete lorlatinib
English: NAME OF THE MEDICINAL PRODUCT Lorviqua 25 mg tablets lorlatinib
Croatian: Lorviqua 25 mg tablete lorlatinib
English: How to store Lorviqua
Croatian: Kako čuvati lijek Lorviqua
English: Gastrointestinal disorders Diarrhoea
Croatian: Poremećaji probavnog sustava Proljev
English: NAME OF THE MEDICINAL PRODUCT Lorviqua 100 mg film-coated tablets lorlatinib
Croatian: Lorviqua 100 mg filmom obložene tablete lorlatinib
English: Oral use.
Croatian: Učinci na govor
English: NAME OF THE MEDICINAL PRODUCT Lorviqua 25 mg film-coated tablets lorlatinib
Croatian: Lorviqua 25 mg filmom obložene tablete lorlatinib
English: Rash (including dermatitis acneiform, maculopapular rash, pruritic rash, rash).
Croatian: j Osip (uključujući akneiformni dermatitis, makulopapularni osip, pruritični osip, osip).
English: Medicinal products whose plasma concentrations may be altered by lorlatinib CYP3A4/5 substrates
Croatian: Lijekovi kojima lorlatinib može promijeniti koncentracije u plazmi
English: Magyarország
Croatian: Danmark
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each film-coated tablet contains 100 mg of lorlatinib.
Croatian: Jedna filmom obložena tableta sadrži 100 mg lorlatiniba.
English: This summary was last updated in April 2017.
Croatian: Sažetak je posljednji put ažuriran u 04.2017.
English: Prevomax is injected once daily under the skin or into a vein (1 mg/per kg bodyweight) for up to five days.
Croatian: Prevomax se primjenjuje jedanput dnevno pod kožu ili u venu (1 mg/kg tjelesne težine) do pet uzastopnih dana.
English: The full EPAR for Prevomax can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Croatian: Cjeloviti EPAR za VMP Prevomax nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
English: To prevent vomiting Prevomax should be given more than one hour in advance of the event that might cause vomiting.
Croatian: Za sprječavanje povraćanja Prevomax treba dati više od jednog sata prije događaja koji može prouzročiti povraćanje.
English: What is Prevomax and what is it used for?
Croatian: Što je Prevomax i za što se koristi?
English: As for every medicine, the company provided studies on the quality of Prevomax.
Croatian: Kao i za svaki lijek, tvrtka je dostavila ispitivanja o kvaliteti VMP-a Prevomax.
English: It is not intended to provide practical advice on how to use Prevomax.
Croatian: Svrha sažetka nije davati praktične savjete o korištenju VMP-a Prevomax.
English: This means that Prevomax contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the EU called Cerenia.
Croatian: To znači da Prevomax sadržava istu djelatnu tvar i djeluje na isti način kao i „referentni lijek” koji je već odobren u Europskoj uniji (EU) pod nazivom Cerenia.
English: The active substance in Prevomax, maropitant, stops a chemical in the body (substance P) from attaching to certain targets called neurokinin-1 (NK1) receptors, which are found on the surface of cells in the part of the brain that controls nausea and vomiting.
Croatian: Djelatna tvar u VMP-u Prevomax, maropitant, sprječava vezivanje kemikalije prisutne u tijelu (tvar P) na određene ciljne tvari pod nazivom receptori neurokinina 1 (NK1) koje se nalaze na površini stanica u dijelu mozga koji upravlja mučninom i povraćanjem.
English: What are the benefits and risks of Prevomax?
Croatian: Koje su koristi i rizici VMP-a Prevomax?
English: Prevomax is a veterinary medicine used in dogs and cats to treat vomiting, in combination with other supportive measures, or to prevent vomiting (except travel sickness).
Croatian: Prevomax je veterinarsko-medicinski proizvod koji se primjenjuje u pasa i mačaka za liječenje povraćanja, u kombinaciji s drugim mjerama potpore ili za sprječavanje povraćanja (osim kad je uzrok bolest kretanja).
English: In dogs Prevomax can also be used both to prevent nausea and vomiting before and after an operation and to improve recovery from general anaesthesia after use of morphine.
Croatian: U pasa se Prevomax može isto tako primjenjivati za sprječavanje mučnine i povraćanja prije i nakon operacije te za poboljšanje u oporavku od opće anestezije nakon upotrebe morfija.
English: By blocking the receptors, maropitant can prevent nausea and vomiting.
Croatian: Blokiranjem dotičnih receptora maropitant može spriječiti mučninu i povraćanje.
English: Therefore, the CVMP's view was that, as for Cerenia, the benefits outweigh the identified risks.
Croatian: Stoga je stav CVMP-a da u slučaju VMP-a Cerenia koristi nadmašuju utvrđene rizike.
English: In cats Prevomax is also used to reduce nausea (signs of feeling sick).
Croatian: U mačaka se Prevomax isto tako primjenjuje za smanjenje mučnine (znakovi osjećaja slabosti).
English: The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that, in accordance with EU requirements, Prevomax has been shown to have comparable quality and to be bioequivalent to Cerenia, solution for injection.
Croatian: Odbor za veterinarsko-medicinske proizvode (CVMP) pri Agenciji zaključio je kako je, u skladu sa zahtjevima EU-a, potvrđeno da Prevomax posjeduje usporedivu kvalitetu te je bioekvivalentan/usporediv s VMP-om Cerenia, otopinom za injekciju.
English: Prevomax is a ‘generic medicine'.
Croatian: Prevomax je „generički VMP”.
English: Prevomax is also used to prevent and treat nausea caused by chemotherapy in dogs.
Croatian: Prevomax se primjenjuje i za sprječavanje i liječenje mučnine u pasa prouzročene kemoterapijom.
English: The European Commission granted a marketing authorisation valid throughout the EU for Prevomax on 19 June 2017.
Croatian: Europska komisija izdala je odobrenje za stavljanje u promet koje je za VMP Prevomax na snazi u Europskoj uniji od 19/06/2017.
English: This is a summary of the European public assessment report (EPAR) for Prevomax.
Croatian: Ovo je sažetak europskoga javnog izvješća o procjeni (EPAR) veterinarsko-medicinskog proizvoda Prevomax.
English: There was no need for ‘bioequivalence' studies to investigate whether Prevomax is absorbed similarly to the reference medicine, Cerenia solution for injection, to produce the same level of the active substance in the blood.
Croatian: Nije bilo potrebe za ispitivanjima bioekvivalencije da bi se istražilo apsorbira li se Prevomax na sličan način kao referentni VMP Cerenia u obliku otopine za injekciju radi proizvodnje jednake razine djelatne tvari u krvi.
English: Studies on the benefits and risks of the active substance in the approved uses have already been carried out with the reference medicine, Cerenia, and do not need to be repeated for Prevomax.
Croatian: Ispitivanja omjera koristi i rizika djelatnih tvari u odobrenoj primjeni već su provedena s referentnim VMP-om Cerenia i ne treba ih ponavljati za VMP Prevomax.
English: Why is Prevomax approved?
Croatian: Zašto je VMP Prevomax odobren?
English: The Committee recommended that Prevomax be approved for use in the EU.
Croatian: Odbor je preporučio izdavanje odobrenja za stavljanje u promet VMP-a Prevomax u EU-u.
English: This is because when given by injection into a vein, the active substance in Prevomax is delivered straight into the bloodstream.
Croatian: To je iz razloga što se injekcijom u venu djelatna tvar u VMP-u Prevomax isporučuje izravno u krvotok.
English: When substance P attaches to these receptors it triggers nausea and vomiting.
Croatian: Kada se tvar P veže na te receptore, uzrokuje mučninu i povraćanje.
English: Prevomax contains the active substance maropitant.
Croatian: Prevomax sadržava djelatnu tvar maropitant.
English: Because Prevomax is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Croatian: Budući da je Prevomax generički VMP te je bioekvivalent referentnom VMP-u, smatra se da su njegove koristi i rizici isti kao i oni referentnog VMP-a.
English: How is Prevomax used?
Croatian: Kako se Prevomax koristi?
English: Other information about Prevomax?
Croatian: Ostale informacije o VMP-u Prevomax
English: The medicine can only be obtained with a prescription and is available as a solution for injection.
Croatian: VMP Prevomax izdaje se samo na veterinarski recept i dostupan je u obliku otopine za injekciju.
English: When given by injection under the skin, the active substance in Prevomax is expected to be absorbed in the same way as the reference medicine.
Croatian: Očekuje se da će se primjenom injekcijom pod kožu djelatna tvar u VMP-u Prevomax apsorbirati na isti način kao i referentni VMP.
English: For practical information about using Prevomax, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Croatian: Praktične informacije o primjeni VMP-a Prevomax vlasnici životinja ili uzgajivači trebaju pročitati u uputi o VMP-u, odnosno trebaju se obratiti svojem veterinaru ili ljekarniku.
English: How does Prevomax work?
Croatian: Kako djeluje Prevomax?
English: Safety information has been included in the summary of product characteristics and the package leaflet for Prevomax, including the appropriate precautions to be followed by healthcare professionals and animal owners or keepers.
Croatian: U sažetku opisa svojstava VMP-a, kao i u uputi o VMP-u Prevomax, nalaze se sigurnosne informacije, uključujući odgovarajuće mjere opreza kojih se veterinari te vlasnici životinja ili uzgajivači trebaju pridržavati.
English: For more information about treatment with Prevomax, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Croatian: VMP-om Prevomax vlasnici životinja ili uzgajivači trebaju pročitati u uputi o VMP-u, odnosno trebaju se obratiti svojem veterinaru ili ljekarniku.
English: How has Prevomax been studied?
Croatian: Kako je VMP Prevomax ispitivan?
English: The precautions are the same as for the reference medicine since Prevomax is a generic medicine.
Croatian: Budući da je Prevomax generički VMP, mjere opreza iste su kao i kod referentnog VMP-a.